Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeoPharm has unveiled positive preclinical data revealing that its novel gemcitabine-cardiolipin conjugate demonstrated lower toxicity and improved anti-tumor activity compared to Eli Lilly's Gemzar.
Subscribe to our email newsletter
This data was presented via a poster session at the 229th Annual Meeting of the American Chemical Society, in San Diego, California. NeoPharm’s poster described synthesis of gemcitabine-cardiolipin conjugate and the in vivo evaluation of its biological activity showing significant tumor growth inhibition and prolonged animal survival in a mouse model.
“This is another example of the potential for NeoPharm’s proprietary NeoLipid technology to potentially improve currently available cancer treatment options,” said Ronald Eidell, NeoPharm’s president and CEO. “Our scientists continue to work on expanding the utility of our NeoLipid technology.”
NeoLipid technology uses an innovative liposome-based system to deliver anticancer drugs to tumors. NeoLipid technology combines drugs or other compounds with the NeoPharm’s proprietary lipids and allows for the creation of a stable liposome. Because tumor cells need to consume large amounts of fats to sustain their extremely rapid growth, they recognize the liposomal drug as a potential source of nutrition.